Self-Monitoring of Blood Glucose to Assess Dawn Phenomenon in Chinese People with Type 2 Diabetes Mellitus

Figure 1

Magnitude of the dawn phenomenon (ΔDawn) in three groups. Group 1, treated with insulin sensitizers (black circle); group 2, treated with insulin secretagogues (black square); and group 3, treated with insulin secretagogues in combination with insulin sensitizers (black triangle). When the threshold of ΔDawn was set at 20 mg/dL, the prevalence of dawn phenomenon in groups 1–3 was 42.5%, 31.5%, and 40.9%, respectively ().